Skip to main content

New Drug Approvals 2011 - Pt. XXXI Asparaginase Erwinia chrysanthemi (ErwinazeTM)

ATC code: L01XX02

On November 18, the FDA approved asparaginase from Erwinia chrysanthemi for the treatment of patient with acute lymphoblastic leukemia (ALL) who have become allergic to the E. coli asparaginase that is conventionally used for the treatment of ALL patients.

ALL is a cancer of the white blood cells and can be fatal within weeks from the onset of the disease if it is left untreated. In ALL, there is an unproportional increase in the population of immature white blood cells, which crowd out functional immune cells as well as red blood cells and platelets, and in advanced stages of the disease infiltrate into tissues and organs, most frequently liver, spleen and lymph nodes. The symptoms of ALL in its initial stages are fatigue, anemia, frequent infections and fever as well as breathlessness and prolonged bleeding. ALL is caused by DNA damage and associated with exposure to radiation and cancerogenic chemicals. There are a number of typical chromosomal translocations, the most frequent in adults with ALL is the so called Philadelphia chromosome, where a translocation of chromosomes 9 and 22 results in the formation of the fusion gene bcr-abl (CHEMBL1862). Treatment of ALL is usually encompasses the three phases i) remission induction, which aims to quickly kill off 95% of the cancerous cells, ii) consolidation to further reduce the tumor burden and iii) maintenance with the aim to prevent a relapse caused by stray surviving leukemic cells.

Aspariginase is part of the remission induction regimen and used in combination with other cytostatic and cytotoxic drugs including prednisolone (CHEMBL131), dexamethasone (CHEMBL384467) , vincristin (CHEMBL303560) and daunorubicin (CHEMBL178). Asparaginase is an enzyme (EC that catalyzes the hydrolysis of asparagine (CHEBI:17196)  to aspartic acid (CHEBI17053) as shown below. Unlike healthy body cells, leukemic cells rely on the presence of extracellular asparagine for protein metabolism and survival, hence the beneficial effect for ALL patients. Conventionally, asparaginase for he treatment of ALL is derived from the bacterium Escherichia coli (corresponds to Uniprot:P00805) but some patients (estimated 10-15%) become allergic to this enzyme. For these patients, the ortholog from the bacterium Erwinia crysanthemi (Uniprot-Id P06608) is available to replace the untolerated treatment.

Asparaginase catalyzes the hydrolysis of asparagine to aspartic acid.
Asparaginase Erwinia crysanthemi is a tetrameric enzyme composed of four identical subunits each weighing about 35kDa. The crystal structures of many asparaginase enzymes are known, including that of the closely related protein from Erwinia carotovora (PDBe:2jk0)

The recommended dosage is 25.000 International Units/m2 (International Units compare biological activity relative to an arbitrary amount of the active ingredient, square meter refers to body surface) three times a week. The route of administration is intramuscular injection.

The pharmakokinetic paramaters of Erwinaze were not determined in clinical trials, serum concentrations greater than 0.1 International Units/mL were reached by all patients within 72 hours of the third injection of aspariginase Erwinia chrysanthemi.

Side effects reported in the study include serious hypersensitivity reactions, pancreatitis, glucose intolerance, thrombosis and hemorrhage.

Asparaginase Erwinia chrysanthemi is marketed in the US by Eusa Pharma under the trade name Erwinaze. In a number of other countries, it is available under the name Erwinase.

Package information can be found here.


Popular posts from this blog

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

ChEMBL 29 Released

  We are pleased to announce the release of ChEMBL 29. This version of the database, prepared on 01/07/2021 contains: 2,703,543 compound records 2,105,464 compounds (of which 2,084,724 have mol files) 18,635,916 activities 1,383,553 assays 14,554 targets 81,544 documents Data can be downloaded from the ChEMBL FTP site: .  Please see ChEMBL_29 release notes for full details of all changes in this release: New Deposited Datasets EUbOPEN Chemogenomic Library (src_id = 55, ChEMBL Document IDs CHEMBL4649982-CHEMBL4649998): The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project to enable and unlock biology in the open. The aims of the project are to assemble an open access chemogenomic library comprising about 5,000 well annotated compounds covering roughly 1,000 different proteins, to synthesiz

Identifying relevant compounds in patents

  As you may know, patents can be inherently noisy documents which can make it challenging to extract drug discovery information from them, such as the key targets or compounds being claimed. There are many reasons for this, ranging from deliberate obfuscation through to the long and detailed nature of the documents. For example, a typical small molecule patent may contain extensive background information relating to the target biology and disease area, chemical synthesis information, biological assay protocols and pharmacological measurements (which may refer to endogenous substances, existing therapies, reaction intermediates, reagents and reference compounds), in addition to description of the claimed compounds themselves.  The SureChEMBL system extracts this chemical information from patent documents through recognition of chemical names, conversion of images and extraction of attached files, and allows patents to be searched for chemical structures of interest. However, the curren

Julia meets RDKit

Julia is a young programming language that is getting some traction in the scientific community. It is a dynamically typed, memory safe and high performance JIT compiled language that was designed to replace languages such as Matlab, R and Python. We've been keeping an an eye on it for a while but we were missing something... yes, RDKit! Fortunately, Greg very recently added the MinimalLib CFFI interface to the RDKit repertoire. This is nothing else than a C API that makes it very easy to call RDKit from almost any programming language. More information about the MinimalLib is available directly from the source . The existence of this MinimalLib CFFI interface meant that we no longer had an excuse to not give it a go! First, we added a BinaryBuilder recipe for building RDKit's MinimalLib into Julia's Yggdrasil repository (thanks Mosè for reviewing!). The recipe builds and automatically uploads the library to Julia's general package registry. The build currently targe

New Drug Warnings Browser

As mentioned in the announcement post of  ChEMBL 29 , a new Drug Warnings Browser has been created. This is an updated version of the entity browsers in ChEMBL ( Compounds , Targets , Activities , etc). It contains new features that will be tried out with the Drug Warnings and will be applied to the other entities gradually. The new features of the Drug Warnings Browser are described below. More visible buttons to link to other entities This functionality is already available in the old entity browsers, but the button to use it is not easily recognised. In the new version, the buttons are more visible. By using those buttons, users can see the related activities, compounds, drugs, mechanisms of action and drug indications to the drug warnings selected. The page will take users to the corresponding entity browser with the items related to the ones selected, or to all the items in the dataset if the user didn’t select any. Additionally, the process of creating the join query is no